Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.56 CHF
−18.64 M CHF
320.83 M CHF
13.28 M
About POLYPEPTIDE N
Sector
Industry
CEO
Juan-José Gonzalez
Website
Headquarters
Baar
Founded
1952
ISIN
CH1110760852
FIGI
BBG0100P02R8
PolyPeptide Group AG engages in the business of development, manufacturing, and marketing of peptide- and oligonucleotide-based compounds for use in the pharmaceutical and related research industries. It operates through the following business areas: Custom Projects, Contract Manufacturing, and Generics and Cosmetics. The Custom Projects business area includes manufacturing of custom research-grade peptides and oligonucleotides for use in pre-clinical and clinical development as well as for regulatory and scientific studies. The Contract Manufacturing business area focuses on peptides for commercial stage peptide therapeutics, at scale, in commercial batches and in accordance with current Good Manufacturing Practice (cGMP) requirements. The Generics and Cosmetics business area is involved in peptide-based generics for the human and veterinary market, produced on an industrial scale following cGMP guidelines. The company was founded in 1952 and is headquartered in Baar, Switzerland.
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of PPGN is 16.70 CHF — it has increased by 7.19% in the past 24 hours. Watch POLYPEPTIDE N stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on SIX exchange POLYPEPTIDE N stocks are traded under the ticker PPGN.
PPGN stock has risen by 4.37% compared to the previous week, the month change is a −8.24% fall, over the last year POLYPEPTIDE N has showed a −41.61% decrease.
We've gathered analysts' opinions on POLYPEPTIDE N future price: according to them, PPGN price has a max estimate of 43.53 CHF and a min estimate of 18.38 CHF. Watch PPGN chart and read a more detailed POLYPEPTIDE N stock forecast: see what analysts think of POLYPEPTIDE N and suggest that you do with its stocks.
PPGN reached its all-time high on Sep 6, 2021 with the price of 147.40 CHF, and its all-time low was 13.22 CHF and was reached on Apr 7, 2025. View more price dynamics on PPGN chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
PPGN stock is 7.84% volatile and has beta coefficient of 1.09. Track POLYPEPTIDE N stock price on the chart and check out the list of the most volatile stocks — is POLYPEPTIDE N there?
Today POLYPEPTIDE N has the market capitalization of 551.04 M, it has increased by 7.23% over the last week.
Yes, you can track POLYPEPTIDE N financials in yearly and quarterly reports right on TradingView.
POLYPEPTIDE N is going to release the next earnings report on Aug 12, 2025. Keep track of upcoming events with our Earnings Calendar.
POLYPEPTIDE N revenue for the last half-year amounts to 189.64 M CHF, despite the estimated figure of 197.63 M CHF. In the next half-year revenue is expected to reach 144.24 M CHF.
PPGN net income for the last half-year is −7.72 M CHF, while the previous report showed −10.95 M CHF of net income which accounts for 29.50% change. Track more POLYPEPTIDE N financial stats to get the full picture.
As of Apr 21, 2025, the company has 1.36 K employees. See our rating of the largest employees — is POLYPEPTIDE N on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. POLYPEPTIDE N EBITDA is 22.10 M CHF, and current EBITDA margin is 6.94%. See more stats in POLYPEPTIDE N financial statements.
Like other stocks, PPGN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade POLYPEPTIDE N stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So POLYPEPTIDE N technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating POLYPEPTIDE N stock shows the sell signal. See more of POLYPEPTIDE N technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.